contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nomination-committee-for-the-2026-annual-general-meeting-in-nanexa-ab-publ

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Nanexa

The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.The members of the Nomination Committee are:Marlon Värnik, ExelityJonas PålssonGöran Ando,...

<div class="mfn-preamble"><p><strong>The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.</strong></p></div><div class="mfn-body"><p>The members of the Nomination Committee are:</p><ul><li>Marlon Värnik, Exelity</li><li>Jonas Pålsson</li><li>Göran Ando, Chairman of the Board, adjunct</li></ul><p>The Nomination Committee's proposals will be presented in the notice to the 2026 Annual General Meeting and on the company's website, <a rel="noopener" href="http://www.nanexa.com/">www.nanexa.com</a>.</p><p>Shareholders may contact the Nomination Committee with suggestions regarding its work by sending e-mail to <a rel="noopener" href="mailto:info@nanexa.se">info@nanexa.se</a> (heading "Nanexa's Nomination Committee") or by letter to: Nanexa AB, Attn: Nanexa's Nomination Committee, Virdings Allé 2, SE-754 50, Uppsala, Sweden.</p><p>The Annual General Meeting will be held in Uppsala on 12 May 2026.</p><p><strong>For further information, please contact:</strong></p></div><div class="mfn-footer mfn-contacts mfn-2376405b3437"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>David Westberg – CEO, Nanexa AB (publ)&nbsp;<br>Phone: +46 70 942 83 03<br>Email:&nbsp;<a rel="noopener" href="mailto:david.westberg@nanexa.se">david.westberg@nanexa.se</a><br><a rel="noopener" href="http://www.nanexa.com/">www.nanexa.com</a></p><p>The company’s Certified Adviser is Tapper Partners AB.</p></div><div class="mfn-footer mfn-about mfn-c9ba281e2dde"><p><strong class="mfn-heading-1">About Nanexa AB (publ)</strong></p><hr><p>Nanexa is bringing the control, precision and versatility of Atomic Layer Deposition (ALD) technology to drug formulation. The company’s proprietary PharmaShell® platform is a unique drug delivery system that enables a high drug load, thus low injection volume, creating a new generation of ‘super generic’ formulations that will provide greater convenience and reduce costs in the treatment of conditions such as metabolic diseases like type 2 diabetes and obesity, hematology/oncology, cardiovascular disorders, psychiatry, and many others.<br>Nanexa develops its own products and also has collaboration agreements with several pharma companies, including the latest license and option agreement with Moderna.</p><p>Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/060eb4b1-84aa-4e9d-b28a-d625aa84a975/nomination-committee-for-the-2026-annual-general-meeting-in-nanexa-ab-publ.pdf" class="mfn-generated mfn-primary">Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)</a></p></div>

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

Neste

Finnair

Kemira

Orthex

Nokian Tyres

Kesko

Tokmanni Group

Puuilo

Öljyn hinnan vaikutus Helsingin pörssiin: historia, vaikutusmekanismit ja riskit

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Euroalueelta inflaatioyllätys jo ennen öljyn hintavaikutusta

Mustan kullan hinta hyppäsi Hormuzinsalmen ongelmien vuoksi

Stagflaatiota pelätään, mutta talouden rakenteet ovat sitä vastaan